At present, the company has established extensive,in-depth and long-term cooperative relationships with many hospitals, and researches on multiple cancers such as lung cancer, colorectal cancer and gynecological tumors.
The research direction covers the screening of early tumor markers and the prognosis, evaluation, tumor heterogeneity molecular classification and other fields, and achieved fruitful results.
We are a leading provider of diagnostic and testing services to pharmaceutical and biotech companies. Our laboratories have met all applicable standards for accreditation, including accreditation from CAP, and have earned top marks in a number of external quality assessments carried out by CAP, EMQN, the Clinical Test Center of the National Health Commission of China and the Center of Clinical Laboratories of Shanghai.
We strive to provide our customers with high-quality, streamlined one-stop testing services. Just some of our many services include:
• Comprehensive platforms: NGS (SNP, Indel, Fusion, TMB, MSI, RNA_Seq, TCR_Seq), multi-color IHC, cytokine panel testing, FISH, single cell, CTC, IHC, karyotyping, flow cytometry
• Clinical trial design for biomarker studies, taking advantage of our large Clinico-Genomics Database (CGDB)
• Companion DX development (Mutation Panels, Gene Expression, IHC/PD-L1)
•“Just in Time” patient recruitment and enrollment (MSI, NTRK, cMet, KRAS, HRD, FGFR)
• Professional project-management services
To date, we have collaborated with more than 20 pharmaceutical and biotech companies to provide testing services for pre-clinical and clinical trials.
Globally, we have formed a strategic partnership with Interpace Biosciences (NASDAQ: IDXG) to offer seamless services to global pharmas for their cross-border multi-center trials.